TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7163015

Group type: EXPERIMENTAL
Intervention: Experimental group (viewed catheterization videotape)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (viewed unrelated control videotape)
Number of subjects: 53
Study: 30666834

Group type: EXPERIMENTAL
Intervention: SPC-prognosis
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: MSI status
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: SPC-Prediction
Number of subjects: 586
Study: 29096682

Group type: EXPERIMENTAL
Intervention: GEE log‐binomial model
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GEE Poisson model
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bayesian binomial GLMM
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GLMM assuming binomial distribution
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GLMM assuming Poisson distribution
Number of subjects: 50

Group type: COMPARATOR
Intervention: Log‐binomial model without adjustment for clustering
Number of subjects: 50
Study: 24944135

Group type: EXPERIMENTAL
Intervention: Recreational football
Number of subjects: 26
Study: 22460082

Group type: COMPARATOR
Intervention: Time-lapse incubator (TLI)
Number of subjects: 59
Study: 20831134

Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer cement (RMGIC)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 5000 ppm sodium fluoride (F‐gel)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: RMGIC
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide amorphous calcium phosphate (CPP‐ACP)
Number of subjects: 4
Study: 17506855

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cetirizine 50 mg (healthy volunteers)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 15677388

Group type: EXPERIMENTAL
Intervention: Fitogenic environment (intervention group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Obesogenic environment (control group)
Number of subjects: 18
Study: 11894723

Group type: EXPERIMENTAL
Intervention: Monophasic OCs containing EE combined with DSG or GST
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Triphasic OCs containing EE combined with GST or NGT
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Monophasic combination of EE and GST
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Monophasic OCs containing EE and GST
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Monophasic OCs containing EE and DSG
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low-dose OCs containing newer gonane progestogens
Number of subjects: 22
Study: 10512908

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MRI
Number of subjects: 43
Study: 7859140

Group type: EXPERIMENTAL
Intervention: Thymopentin, 50 mg subcutaneously 3 times per week
Number of subjects: 352
Study: 1777589

Group type: EXPERIMENTAL
Intervention: Long-term antibiotic prophylaxis with trimethoprim-sulfamethoxasole
Number of subjects: 65

Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 65
Study: 6352004

Group type: COMPARATOR
Intervention: Cisplatin (80 mg/m2) every 3 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cisplatin plus weekly methotrexate (250 mg/m2) with leucovorin
Number of subjects: 80
Study: 31851158

Group type: EXPERIMENTAL
Intervention: Trimodal therapy (TMT) consisting of maximal transurethral resection of the bladder tumor followed by concurrent radiosensitizing chemotherapy and radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bladder-sparing therapies (including partial cystectomy, radiation monotherapy, and radical transurethral resection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radical cystectomy
Number of subjects: 0
Study: 30042516

Group type: EXPERIMENTAL
Intervention: Whey protein concentrate (WPC)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Soy protein concentrate (SPC)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 47
Study: 26907659

Group type: EXPERIMENTAL
Intervention: Twice-daily low-molecular weight heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring antifactor Xa activity levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reexposure to asparaginase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platelet transfusion to maintain platelet count >50×10/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duration of anticoagulation for line-associated thrombosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duration of anticoagulation for cerebral sinovenous thrombosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Central venous access device insertion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Removal of central venous access devices
Number of subjects: 0
Study: 25025601

Group type: EXPERIMENTAL
Intervention: Iyengar yoga (IY) program, 6-week duration, twice per week
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual-care waitlist control group
Number of subjects: 51
Study: 22008735

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg) + Gaboxadol (10 mg)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg) + Gaboxadol (5 mg)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study: 20869711

Group type: EXPERIMENTAL
Intervention: Endoscopic Sphincterotomy (ES)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Endoscopic Papillary Balloon Dilation (EPBD)
Number of subjects: 282
Study: 17157479

Group type: EXPERIMENTAL
Intervention: Low-power laser (LPL) irradiation immediately after operation (energy output 4 J/cm2, power density 50 mW, wavelength 637 nm)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 4 mg dexamethasone (Dexason) into the internal pterygoid muscle
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: LPL irradiation supplemented by systemic dexamethasone (4 mg i.m. in deltoid region, followed by 4 mg intraorally 6h postoperatively)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual postoperative recommendations (cold packs, soft diet, etc.)
Number of subjects: 120
Study: 17531730

Group type: EXPERIMENTAL
Intervention: Ulnar artery approach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Radial artery approach
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ulnar artery approach with strong pulse
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ulnar artery approach with weak pulse
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ulnar artery and Radial artery approaches
Number of subjects: 100
Study: 15205922

Group type: EXPERIMENTAL
Intervention: FDG PET combined with CT
Number of subjects: 55

Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: FDG PET
Number of subjects: 55
Study: 11053821

Group type: EXPERIMENTAL
Intervention: 200 ml aprotinin (Trasylol, Bayer AG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 200 ml physiological saline solution
Number of subjects: 20
Study: 9363289

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg per day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 1425866

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 10
Study: 6397218

Group type: EXPERIMENTAL
Intervention: Nicardipine 20 mg, three times daily
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nicardipine slow release 30 mg, twice daily
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31021123

Group type: EXPERIMENTAL
Intervention: Telemedicine integrated into primary care (ITM)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Quitline‐like phone counseling (QL)
Number of subjects: 560
Study: 29784009

Group type: EXPERIMENTAL
Intervention: Non-numeric and numeric information complemented by crowd-figure-pictograms
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Non-numeric and numeric information
Number of subjects: 552

Group type: COMPARATOR
Intervention: Non-numeric information (control group)
Number of subjects: 552
Study: 26418369

Group type: EXPERIMENTAL
Intervention: HMB supplementation with HIIT (S)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Placebo with HIIT (P)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 37
Study: 24396060

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (2 μg kg(‐1) min(‐1))
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 11
Study: 22442733

Group type: EXPERIMENTAL
Intervention: Active gameplay of Re-Mission videogame
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive exposure to gameplay audio-visual stream
Number of subjects: 0
Study: 19129422

Group type: EXPERIMENTAL
Intervention: AZD7009 30-minute 3.25 mg/min
Number of subjects: 168

Group type: COMPARATOR
Intervention: AZD7009 15-minute 3.25 mg/min
Number of subjects: 168

Group type: COMPARATOR
Intervention: AZD7009 15-minute 4.4 mg/min
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo (combined)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: AZD7009 30-minute 3.25 mg/min (AF episodes <=30 days)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo followed by DC cardioversion (AF episodes <=30 days)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: AZD7009 best-dose group
Number of subjects: 168
Study: 17645251

Group type: EXPERIMENTAL
Intervention: BA plus scalp acupuncture (SA) group (B group)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: BA plus abdominal acupuncture (AA) group (C group)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: BA plus SA plus AA group (D group)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Body acupuncture (BA) group (A group)
Number of subjects: 152
Study: 15734231

Group type: EXPERIMENTAL
Intervention: Active 2mg nicotine lozenge
Number of subjects: 917

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 917
Study: 12190711

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention program including collaborative treatment plan, monthly telephone monitoring by a nurse care manager, feedback of monitoring results, algorithm-based medication recommendations, outreach and care coordination, structured psychoeducational group program (Life Goals Program).
Number of subjects: 441

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 441
Study: 9855417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 0
Study: 7814823

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg oral dose)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg i.v. administered 5 days before baseline)
Number of subjects: 28
Study: 2815976

Group type: EXPERIMENTAL
Intervention: Purified chick embryo cell (PCEC) rabies vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human diploid cell rabies vaccine (HDCV)
Number of subjects: 0
Study: 1090337

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 mu g)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 mu g)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of salbutamol and ipratropium bromide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31741992

Group type: EXPERIMENTAL
Intervention: Bilateral glossopharyngeal nerve block with bupivacaine
Number of subjects: 64

Group type: COMPARATOR
Intervention: No glossopharyngeal nerve block
Number of subjects: 64
Study: 28166501

Group type: EXPERIMENTAL
Intervention: Sniff-controlled self-activated FES
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Caregiver activated FES
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Button self-activated FES
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Manual assistance of a caregiver
Number of subjects: 14

Group type: COMPARATOR
Intervention: All assisted methods
Number of subjects: 14
Study: 27189595

Group type: EXPERIMENTAL
Intervention: FENO-based asthma management (adjusted inhaled corticosteroid dose based on FENO levels)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care (one clinical assessment of asthma, self-management education, treatment changes by general practitioner)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: FENO-based asthma management
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 600
Study: 23692321

Group type: EXPERIMENTAL
Intervention: Carisbamate 400 mg/day
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Carisbamate 800 mg/day
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Carisbamate 1200 mg/day
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 614

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Dizziness (adverse event)
Number of subjects: 614
Study: 21968546

Group type: EXPERIMENTAL
Intervention: Flow rate adjusted to heart rate (Group 1: dosage/16)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Fixed flow rate (Group 3)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Flow rate based on scan time + 8 (Group 2)
Number of subjects: 296
Study: 19535468

Group type: EXPERIMENTAL
Intervention: Improvisational music therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Toy play sessions
Number of subjects: 10
Study: 17475962

Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET studies at 1 and 3 weeks after chemotherapy initiation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET studies
Number of subjects: 16
Study: 15727386

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no PTX)
Number of subjects: 20
Study: 12548530

Group type: EXPERIMENTAL
Intervention: Prednisone (low-dose, alternate-day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 8
Study: 10588224

Group type: EXPERIMENTAL
Intervention: High-dose enalapril (40 mg daily)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Low-dose enalapril (5 mg daily)
Number of subjects: 75
Study: 8942297

Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (240 mg b.i.d.), metronidazole (250 mg t.i.d.), and amoxicillin (500 mg t.i.d.) for 14 days (Group 1)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg b.i.d.) and amoxicillin (1000 mg b.i.d.) for 14 days (Group 2)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg b.i.d.), metronidazole (250 mg t.i.d.), and amoxicillin (500 mg t.i.d.) for 14 days (Group 3)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg q.d.) and amoxicillin (500 mg t.i.d.) for 14 days followed by tripotassium dicitrato bismuthate (240 mg b.i.d.) and nizatidine (150 mg q.d.) for 14 days (Group 4)
Number of subjects: 180
Study: 1944902

Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tridihexethyl chloride
Number of subjects: 10
Study: 7068113

Group type: EXPERIMENTAL
Intervention: chenodeoxycholic acid (CDCA) 375 or 750 mg g.d. for 2 years
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: chenodeoxycholic acid (CDCA)
Number of subjects: 126
Study: 30804311

Group type: EXPERIMENTAL
Intervention: Rotary Kedo-S files
Number of subjects: 75

Group type: COMPARATOR
Intervention: Hand K-files
Number of subjects: 75

Group type: COMPARATOR
Intervention: H-files
Number of subjects: 75
Study: 29238184

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid treatment
Number of subjects: 13591

Group type: EXPERIMENTAL
Intervention: Baseline pulmonary maintenance medication
Number of subjects: 13591

Group type: COMPARATOR
Intervention: No specific intervention mentioned
Number of subjects: 13591
Study: 27084659

Group type: EXPERIMENTAL
Intervention: Proton therapy (arm A)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Carbon ion therapy (arm B)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Both therapies (Proton and Carbon ion)
Number of subjects: 92
Study: 25149894

Group type: EXPERIMENTAL
Intervention: Baru almonds supplementation (20 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (1 corn starch capsule/day)
Number of subjects: 20
Study: 22573845

Group type: EXPERIMENTAL
Intervention: Triple ARV (zidovudine, lamivudine, and lopinavir/ritonavir during pregnancy and breastfeeding)
Number of subjects: 824

Group type: COMPARATOR
Intervention: AZT/sdNVP (zidovudine until delivery with single-dose nevirapine without postpartum prophylaxis)
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: Triple ARV
Number of subjects: 824

Group type: COMPARATOR
Intervention: AZT/sdNVP
Number of subjects: 824
Study: 19509551

Group type: EXPERIMENTAL
Intervention: Acupuncture plus vitamin B6 PC6 points injection
Number of subjects: 142

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 142

Group type: COMPARATOR
Intervention: Vitamin B6 alone
Number of subjects: 142
Study: 17484670

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy based on supportive-expressive therapy, tailored for social phobia.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study: 16080084

Group type: EXPERIMENTAL
Intervention: Patient-delivered partner treatment (PDPT)
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: Booklet-enhanced partner referral (BEPR)
Number of subjects: 977

Group type: COMPARATOR
Intervention: Standard partner referral (PR)
Number of subjects: 977
Study: 12504971

Group type: EXPERIMENTAL
Intervention: Immediate pushing
Number of subjects: 170

Group type: COMPARATOR
Intervention: Delayed pushing
Number of subjects: 170
Study: 9164180

Group type: EXPERIMENTAL
Intervention: Subtotal lymphoid irradiation (STLI)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Vinblastine, methotrexate, and bleomycin (VBM) chemotherapy and regional radiotherapy
Number of subjects: 78
Study: 8428718

Group type: EXPERIMENTAL
Intervention: Propranolol (0.15 mg/kg intravenously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3618714

Group type: EXPERIMENTAL
Intervention: Tono-Pen tonometer
Number of subjects: 270

Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 270
Study: 31783741

Group type: EXPERIMENTAL
Intervention: Poor knowledge of menstruation
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Use of absorbent materials
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Cleaning external genitalia
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Menstrual hygienic practice
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Age less than 15 years
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Longer days of menstrual flow
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Poor knowledge of menses
Number of subjects: 791
Study: 28958328

Group type: EXPERIMENTAL
Intervention: DDD-CLS pacing for 12 months
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham DDI mode for 12 months
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: DDD-CLS pacing
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham DDI mode
Number of subjects: 46
Study: 27537387

Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 10 mg oral medroxyprogesterone acetate (MPA) for 10 days per cycle
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 10 mg oral MPA daily for 6 months
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Changes in intracellular bodies
Number of subjects: 153
Study: 24852952

Group type: EXPERIMENTAL
Intervention: Systematic offer for a relative to witness CPR
Number of subjects: 570

Group type: COMPARATOR
Intervention: Control group (traditional practice)
Number of subjects: 570
Study: 21945889

Group type: EXPERIMENTAL
Intervention: HEARTY exercise intervention (a combination of healthy eating, aerobic, and resistance exercise)
Number of subjects: 44
Study: 18721830

Group type: EXPERIMENTAL
Intervention: Contour present but not perceived
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contour absent (no contour)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contour present and perceived
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contour not detected
Number of subjects: 0
Study: 17895895

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG supplementation (1-2 x 10(10) per day)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Simplified de Gramont regimen
Number of subjects: 150

Group type: COMPARATOR
Intervention: Mayo regimen
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Guar gum supplementation (11 g per day)
Number of subjects: 150
Study: 15118279

Group type: EXPERIMENTAL
Intervention: Serum total cholesterol concentration during follow-up
Number of subjects: 4349

Group type: EXPERIMENTAL
Intervention: High concentrations of serum HDL cholesterol
Number of subjects: 4349

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 4349

Group type: COMPARATOR
Intervention: Hypertension and smoking
Number of subjects: 4349
Study: 11396814

Group type: EXPERIMENTAL
Intervention: Cisapride (0.2 mg/kg dose three times daily)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 9757196

Group type: EXPERIMENTAL
Intervention: Epirubicin (30-40 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (6-8 mg)
Number of subjects: 26
Study: 8140875

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Epidural bupivacaine
Number of subjects: 9
Study: 3061042

Group type: EXPERIMENTAL
Intervention: 4 times 10 Gy afterloading therapy combined with 45 Gy percutaneous telecobalt therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 times 8 Gy afterloading therapy combined with 45 Gy percutaneous telecobalt therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8 times 5 Gy afterloading therapy combined with 45 Gy percutaneous telecobalt therapy
Number of subjects: 0
Study: 1467634

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (1.2 mg sublingually)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nifedipine (10 mg capsule, chewed and swallowed)
Number of subjects: 40